Advertisement

Oral glucose-stimulated growth hormone (GH) test in adult GH deficiency patients and controls: Potential utility of a novel test

      Highlights

      • Oral glucose initially decreases and subsequently stimulates GH secretion.
      • After oral glucose the best peak GH cut-point for the diagnosis of adult GH deficiency was 1.0 μg/L.
      • The oral glucose test could be a cheap, safe, convenient and effective test for the diagnosis of adult GH deficiency.

      Abstract

      Context

      The diagnosis of adult GH deficiency requires confirmation with a GH stimulation test. Oral glucose (OG) administration affects GH secretion, initially decreasing and subsequently stimulating GH secretion.

      Objective

      The aim of this study was to investigate the diagnostic efficacy and safety of a long OG test (LOGT) as a stimulus of GH secretion for the diagnosis of adult GH deficiency (AGHD).

      Design

      Prospective experimental cross-sectional study.

      Settings

      The study was conducted at the Endocrinology department of the University Hospital of a Coruña, Spain.

      Participants and methods

      We included 60 (40 women) AGHD patients (15) and controls (45) paired 1:3, of similar age, sex and BMI. The area under the curve (AUC) and peak were calculated for GH. The Mann-Whitney test was used to compare the different groups. ROC curve analyses were used. p-Values < 0.05 were considered as statistically significant.

      Interventions

      The intervention consisted of orally administering 75 g oral glucose administration; GH was obtained every 30 min for a total of 300 min.

      Main outcome measurement

      Peak GH area under receiver operating characteristic curve (ROC-AUC) following LOGT.

      Results

      Peak GH (μg/L) levels were lower in the AGHD patients (0.26 ± 0.09) than in the controls (4.00 ± 0.45), p < 0.001. After LOGT, with the ROC plot analysis the best peak GH cut-point was 1.0 μg/L, with 100% sensitivity, 78% specificity, ROC-AUC of 0.9089 and 81.82% accuracy. There were no relevant adverse events during any of the LOGT.

      Conclusions

      The LOGT could be a cheap, safe, convenient and effective test for the diagnosis of AGHD.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Higham C.E.
        • Johannsson G.
        • Shalet S.M.
        Hypopituitarism.
        Lancet. 2016; 388: 2403-2415
        • Molitch M.E.
        • Clemmons D.R.
        • Malozowski S.
        • Merriam G.R.
        • Vance M.L.
        Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline.
        J Clin Endocrinol Metab. 2011; 96: 1587-1609
        • Ho K.K.
        Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia.
        Eur J Endocrinol. 2007; 157: 695-700
        • Hoffman A.R.
        • Strasburger C.J.
        • Zagar A.
        • Blum W.F.
        • Kehely A.
        • Hartman M.L.
        Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing.
        J Clin Endocrinol Metab. 2004; 89: 3224-3233
        • Gazzaruso C.
        • Gola M.
        • Karamouzis I.
        • Giubbini R.
        • Giustina A.
        Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH—an update.
        J Clin Endocrinol Metab. 2014; 99: 18-29
        • Elbornsson M.
        • Horvath A.
        • Gotherstrom G.
        • Bengtsson B.A.
        • Johannsson G.
        • Svensson J.
        Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency.
        Eur J Endocrinol. 2017; 176: 99-109
        • Elbornsson M.
        • Gotherstrom G.
        • Bosaeus I.
        • Bengtsson B.A.
        • Johannsson G.
        • Svensson J.
        Fifteen years of GH replacement improves body composition and cardiovascular risk factors.
        Eur J Endocrinol. 2013; 168: 745-753
        • Biller B.M.
        • Samuels M.H.
        • Zagar A.
        • Cook D.M.
        • Arafah B.M.
        • Bonert V.
        • et al.
        Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency.
        J Clin Endocrinol Metab. 2002; 87: 2067-2079
        • Yuen K.C.
        • Biller B.M.
        • Molitch M.E.
        • Cook D.M.
        Clinical review: is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency?.
        J Clin Endocrinol Metab. 2009; 94: 2702-2707
        • Gordon M.B.
        • Levy R.A.
        • Gut R.
        • Germak J.
        Trends in growth hormone stimulation testing and growth hormone dosing in adult growth hormone deficiency patients: results from the answer program.
        Endocr Pract. 2016; 22: 396-405
        • Berg C.
        • Meinel T.
        • Lahner H.
        • Yuece A.
        • Mann K.
        • Petersenn S.
        Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery.
        Eur J Endocrinol. 2010; 162: 477-482
        • Leong K.S.
        • Walker A.B.
        • Martin I.
        • Wile D.
        • Wilding J.
        • MacFarlane I.A.
        An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease.
        Clin Endocrinol (Oxf). 2001; 54: 463-468
        • Tavares A.B.
        • Seixas-da-Silva I.A.
        • Silvestre D.H.
        • Paixao Jr., C.M.
        • Vaisman M.
        • Conceicao F.L.
        Potential risks of glucagon stimulation test in elderly people.
        Growth Horm IGF Res. 2015; 25: 53-56
        • Rasmussen M.H.
        • Hvidberg A.
        • Juul A.
        • Main K.M.
        • Gotfredsen A.
        • Skakkebaek N.E.
        • et al.
        Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects.
        J Clin Endocrinol Metab. 1995; 80: 1407-1415
        • Cordido F.
        • Penalva A.
        • Dieguez C.
        • Casanueva F.F.
        Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.
        J Clin Endocrinol Metab. 1993; 76: 819-823
        • Popovic V.
        Approach to testing growth hormone (GH) secretion in obese subjects.
        J Clin Endocrinol Metab. 2013; 98: 1789-1796
        • Cordido F.
        • Alvarez-Castro P.
        • Isidro M.L.
        • Casanueva F.F.
        • Dieguez C.
        Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
        Eur J Endocrinol. 2003; 149: 117-122
        • Cordido F.
        • Fernandez T.
        • Martinez T.
        • Penalva A.
        • Peino R.
        • Casanueva F.F.
        • et al.
        Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
        J Clin Endocrinol Metab. 1998; 83: 4350-4354
        • Corneli G.
        • Di Somma C.
        • Baldelli R.
        • Rovere S.
        • Gasco V.
        • Croce C.G.
        • et al.
        The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index.
        Eur J Endocrinol. 2005; 153: 257-264
        • Iranmanesh A.
        • Lawson D.
        • Veldhuis J.D.
        Distinct metabolic surrogates predict basal and rebound GH secretion after glucose ingestion in men.
        J Clin Endocrinol Metab. 2012; 97: 2172-2179
        • Valcavi R.
        • Zini M.
        • Volta C.
        • Ghizzoni L.
        • Azzarito C.
        • Bernasconi S.
        • et al.
        Effects of oral glucose administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH release in children and adults.
        J Clin Endocrinol Metab. 1994; 79: 1152-1157
        • Pena-Bello L.
        • Pertega-Diaz S.
        • Outeirino-Blanco E.
        • Garcia-Buela J.
        • Tovar S.
        • Sangiao-Alvarellos S.
        • et al.
        Effect of oral glucose administration on rebound growth hormone release in normal and obese women: the role of adiposity, insulin sensitivity and ghrelin.
        PLoS One. 2015; 10e0121087
        • Grottoli S.
        • Procopio M.
        • Maccario M.
        • Zini M.
        • Oleandri S.E.
        • Tassone F.
        • et al.
        In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.
        J Clin Endocrinol Metab. 1997; 82: 2261-2265
        • Garcia J.M.
        • Swerdloff R.
        • Wang C.
        • Kyle M.
        • Kipnes M.
        • Biller B.M.
        • et al.
        Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency.
        J Clin Endocrinol Metab. 2013; 98: 2422-2429
        • Gasco V.
        • Beccuti G.
        • Baldini C.
        • Prencipe N.
        • Di Giacomo S.
        • Berton A.
        • et al.
        Acylated ghrelin as a provocative test for the diagnosis of GH deficiency in adults.
        Eur J Endocrinol. 2013; 168: 23-30
        • Hawkes C.P.
        • Mavinkurve M.
        • Fallon M.
        • Grimberg A.
        • Cody D.C.
        Serial GH measurement after intravenous catheter placement alone can detect levels above stimulation test thresholds in children.
        J Clin Endocrinol Metab. 2015; 100: 4357-4363
        • Aimaretti G.
        • Baffoni C.
        • DiVito L.
        • Bellone S.
        • Grottoli S.
        • Maccario M.
        • et al.
        Comparisons among old and new provocative tests of GH secretion in 178 normal adults.
        Eur J Endocrinol. 2000; 142: 347-352
        • Rahim A.
        • Toogood A.A.
        • Shalet S.M.
        The assessment of growth hormone status in normal young adult males using a variety of provocative agents.
        Clin Endocrinol (Oxf). 1996; 45: 557-562
        • Dichtel L.E.
        • Yuen K.C.
        • Bredella M.A.
        • Gerweck A.V.
        • Russell B.M.
        • Riccio A.D.
        • et al.
        Overweight/obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency.
        J Clin Endocrinol Metab. 2014; 99: 4712-4719
        • Yuen K.C.
        • Biller B.M.
        • Katznelson L.
        • Rhoads S.A.
        • Gurel M.H.
        • Chu O.
        • et al.
        Clinical characteristics, timing of peak responses and safety aspects of two dosing regimens of the glucagon stimulation test in evaluating growth hormone and cortisol secretion in adults.
        Pituitary. 2013; 16: 220-230
        • Ogden C.L.
        • Carroll M.D.
        • Kit B.K.
        • Flegal K.M.
        Prevalence of obesity in the United States, 2009–2010.
        NCHS Data Brief. 2012; : 1-8
        • Gutierrez-Fisac J.L.
        • Guallar-Castillon P.
        • Leon-Munoz L.M.
        • Graciani A.
        • Banegas J.R.
        • Rodriguez-Artalejo F.
        Prevalence of general and abdominal obesity in the adult population of Spain, 2008–2010: the ENRICA study.
        Obes Rev. 2012; 13: 388-392
        • Ng M.
        • Fleming T.
        • Robinson M.
        • Thomson B.
        • Graetz N.
        • Margono C.
        • et al.
        Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013.
        Lancet. 2014; 384: 766-781
        • Iranmanesh A.
        • Lizarralde G.
        • Veldhuis J.D.
        Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life endogenous GH in healthy men.
        J Clin Endocrinol Metab. 1991; 73: 1081-1088
        • Cordido F.
        • Peino R.
        • Penalva A.
        • Alvarez C.V.
        • Casanueva F.F.
        • Dieguez C.
        Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
        J Clin Endocrinol Metab. 1996; 81: 914-918
        • Luque R.M.
        • Kineman R.D.
        Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function.
        Endocrinology. 2006; 147: 2754-2763
        • Gomez J.M.
        • Espadero R.M.
        • Escobar-Jimenez F.
        • Hawkins F.
        • Pico A.
        • Herrera-Pombo J.L.
        • et al.
        Growth hormone release after glucagon as a reliable test of growth hormone assessment in adults.
        Clin Endocrinol (Oxf). 2002; 56: 329-334
        • Hamrahian A.H.
        • Yuen K.C.
        • Gordon M.B.
        • Pulaski-Liebert K.J.
        • Bena J.
        • Biller B.M.
        Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study.
        Pituitary. 2016; 19: 332-341
        • Yuen K.C.
        • Tritos N.A.
        • Samson S.L.
        • Hoffman A.R.
        • Katznelson L.
        American Association of Clinical Endocrinologists and American College of Endocrinology disease state clinical review: update on growth hormone stimulation testing and proposed revised cut-point for the glucagon stimulation test in the diagnosis of adult growth hormone deficiency.
        Endocr Pract. 2016; 22: 1235-1244
        • Clemmons D.R.
        Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays.
        Clin Chem. 2011; 57: 555-559